IQVIA Holdings Inc. $IQV Stock Holdings Lifted by Broyhill Asset Management LLC

Broyhill Asset Management LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 15.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 27,010 shares of the medical research company’s stock after buying an additional 3,560 shares during the quarter. IQVIA comprises 4.5% of Broyhill Asset Management LLC’s holdings, making the stock its 3rd largest position. Broyhill Asset Management LLC’s holdings in IQVIA were worth $5,130,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in IQV. Claret Asset Management Corp raised its stake in IQVIA by 1.1% during the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock worth $860,000 after purchasing an additional 49 shares during the period. Versant Capital Management Inc grew its stake in shares of IQVIA by 6.3% in the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock valued at $171,000 after buying an additional 53 shares during the period. Private Advisor Group LLC increased its holdings in shares of IQVIA by 1.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after buying an additional 63 shares during the last quarter. CVA Family Office LLC raised its position in shares of IQVIA by 11.6% during the 3rd quarter. CVA Family Office LLC now owns 654 shares of the medical research company’s stock valued at $124,000 after buying an additional 68 shares during the period. Finally, Huntington National Bank lifted its holdings in IQVIA by 7.8% in the third quarter. Huntington National Bank now owns 969 shares of the medical research company’s stock valued at $184,000 after acquiring an additional 70 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of IQV opened at $164.78 on Friday. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The stock has a market capitalization of $27.96 billion, a PE ratio of 20.96, a PEG ratio of 1.57 and a beta of 1.39. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a 50-day simple moving average of $201.58 and a 200-day simple moving average of $206.67.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. During the same period in the prior year, the firm posted $3.12 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on IQV shares. Jefferies Financial Group cut their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. Royal Bank Of Canada initiated coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price target on the stock. Finally, TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and increased their price objective for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, IQVIA presently has an average rating of “Buy” and an average target price of $229.13.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.